Acquires worldwide rights to several melatonin-modulating compounds from Whitby Research Inc., a subsidary of Ethyl Corp. Interneuron claims that the compounds have potential applications in the treatment of depression, fertility and sleep disorders, jet lag and chronic fatigue syndrome. According to Charles Casamento, president and CEO of Interneuron, the company "is most interested in depression and insomnia" applications of the compounds. Casamento says that clinical trials for any of the compounds are "a year and a half to two years away".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth